Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
4 hedge funds and large institutions have $110K invested in Third Harmonic Bio in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
1% less capital invested
Capital invested by funds: $111K → $110K (-$1.54K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$1.54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| $107K | -$1.54K | -287 | -1% |
|
|
GI
2
GAMMA Investing
Foster City,
California
| $2.46K | – | – | – |
|
|
SS
3
SBI Securities
Tokyo,
Japan
| $1 | – | – | – |
|
THRD Hedge Fund Activity: Q1 2026 in Review
4 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q1 2026, worth a combined $110K — down 1.4% from $111K a quarter earlier.
Fund positioning in THRD was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was RhumbLine Advisers, cutting an estimated $1.54K.
- 4 institutional investors held Third Harmonic Bio (THRD) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $110K of Third Harmonic Bio stock for Q1 2026, down 1.4% quarter-over-quarter.
- 0 funds opened new Third Harmonic Bio positions in Q1 2026 and 0 closed out.
- The largest Third Harmonic Bio seller in Q1 2026 was RhumbLine Advisers, an estimated $1.54K sold.
Based on aggregated 13F filings for Q1 2026.